FAB Pharma raises series A to fund former Mutabilis programme
This article was originally published in Scrip
FAB Pharma, a corporate spin-out from the former French biotechnology company Mutabilis, has raised a series A round of €2.3 million led by the French venture capital firms CDC Innovation and Bioam Gestion. The US-based hedge fund Redmile Group also participated.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.